Introduction
Platelet adhesion at sites of vascular injury is a crucial step in initiating haemostasis and thrombosis. Platelets adhere to the damaged vessel wall directly through collagen receptors (␣ 2 ␤ 1 , glycoprotein [GP]VI, GPIV, . . .) and indirectly through von Willebrand factor (vWF) which forms a bridge between collagen and the platelet GPIb/IX/V. The role of vWF in platelet adhesion is especially important at high shear rates (2) where the rapid interaction between vWF and GPIb␣ slows down the platelets (3, 4) . This event allows consequent irreversible adhesion of the platelets through the collagen receptors.
vWF is composed of 250 kDa subunits which form disulfide linked multimers of up to 20 million Da. The subunit of vWF is composed of 5 different types of domains (D, A, B, C and CK) of which the A1-and A3-domains have important biological functions (5) . The A1-domain is a positively charged region with negatively charged flanking sequences and contains the binding site for GPIb␣ (6) . The A3-domain is negatively charged and contains the main binding site of vWF to type III and type I collagens (7, 8) . On the other hand, the A1-domain was shown to be the main binding site for GuHCl-extracted collagen type VI under static conditions (9) whereas a cooperative binding of A1-and A3-domains plays a pivotal role in the interaction with urea-extracted collagen type VI at high shear rates (10) .
In previous work we identified peptides, selected by phage display, that inhibit vWF-binding to collagen (1) . Phages were selected on an anti-vWF mAb 82D6A3, which interacts with the A3-domain and inhibits vWF-binding to fibrillar collagen types I and III (9) . After a third round of panning two phages that bound to mAb 82D6A3 and to rat tail collagen were selected. Both phages were able to inhibit vWF-binding to collagen and also vWF was able to displace the phages from collagen in a dose-dependent manner. Sequence determination of the cyclic peptides on the phages revealed an almost identical sequence with substitution of an N for a Q:CVWLWEN/QC. Those two peptides were synthesized and both peptides inhibited the vWF-binding to rat tail, calf skin and human collagen type I but the inhibitory concentrations were 5 to 10 times higher for inhibition to calf skin and human collagen than to rat tail collagen. The sequence of the peptides could be aligned with a region in vWF just outside the A3-domain at position 1129-1136.
To study whether this sequence alignment indeed resulted in the identification of a new collagen binding site in vWF, hence whether this region in vWF would also contribute to collagen binding, we made a mutant vWF where amino acids common to the N-, the Q-peptide and the aligned vWF sequence were changed to alanine and performed binding studies of this mutant vWF to different types of collagen and compared its binding affinity with that of WTand ⌬A3-vWF.
Materials and Methods

Materials
Mab 82D6A3 and GuHCl-extracted collagen type VI were a gift of Dr. M. Hoylaerts (Leuven, Belgium). Restriction enzymes were from New England Biolabs (Hitchin, England). Primers were synthesized by Eurogentec (Herstal, Belgium). 
Construction of Mutant vWF
The mutant 7.8-vWF, where 1129-1136 VWTLPDQC was changed into VATAPAAC, was constructed with the QuickChange™Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) as described by the manufacturer. A pBluescript plasmid containing the BamHI-EcoRV-vWF fragment (~8.4 kbp), digested from pNUT-vWF cassette vector (11) , was used as a template instead of the intact pNUT-vWF cassette vector (14578 bp). The sequence of the primers bearing the desired mutations are given in Fig. 1 . The primers contain an extra EagI site for identification of positive clones.
From positive pBluescript plasmids, the NheI-EcoRV-vWF-fragment (part of the BamHI-EcoRV-fragment) was digested and ligated (12) into an NheI-EcoRV-digested pNUT-vWF-cassette vector. The presence of the mutations in the resulting pNUT-vWF-plasmid was confirmed through DNA sequencing.
Plasmid Purification
Plasmid DNA used for DNA sequence analysis and for transfection was prepared with the QIAGEN Plasmid Purification Kit (Qiagen, Westburg, Hilden, Germany).
DNA Sequencing
DNA sequence analysis (13) was performed with the T7 sequencing Kit (Pharmacia, Biotech, Uppsala, Sweden) and samples were analysed on a manual sequence apparatus (BioRad, Hercules, USA).
Transfection and Selection of Stable Transformants
For transfection of pNUT-vWF-mutant a fur-BHK cell line overexpressing furin was used as described (7) . Briefly, pNUT-vWF containing cells were selected with 100 M methotrexate (Sigma, St. Louis, MO). Cell culture supernatant was harvested every 3-4 days. A vWF:Ag ELISA (see below) was used to estimate the expression yield of recombinant vWF (rvWF).
Purification
WT-vWF, ⌬A3-vWF (7) and 7.8-vWF were purified from the culture supernatant by a combination of ion exchange chromatography and heparin chromatography as described (14) . Cell culture supernatant was applied onto a Fractogel EMD-TMAE column (Merck, Darmstadt, Germany) equilibrated in 20 mM Tris-HCl buffer pH 7.4 (Tris buffer). The column was washed with 180 mM NaCl in Tris buffer and vWF was eluted with 280 mM NaCl in Tris buffer. Fractions containing vWF were pooled for the binding studies or were diluted to 90 mM NaCl with Tris buffer and applied onto a Fractogel EMDheparin column (Merck). The column was washed with 100 mM NaCl in Tris buffer and vWF was eluted stepwise with 3 different NaCl concentrations in Tris buffer. Mainly low molecular weight (LMW) multimers of vWF were eluted with 160 mM NaCl, intermediate molecular weight (MMW) fractions of vWF were eluted with 230 mM NaCl and high molecular weight multimers (HMW) of vWF were eluted with 280 mM NaCl.
vWF:Ag ELISA
Microtiter plates (96-well) were coated overnight at 4°C with 125 l/well of a polyclonal anti-vWF-Ig-solution (Dako, Glostrup, Denmark) (1/1000 in 50 mM carbonate buffer pH 9.6). The plates were blocked for 2 h at room temperature (RT) with 250 l/well of a 3% milkpowder solution. Then, as a standard, a plasma pool (in triplicate) was applied to the wells at 1/40 to 1/2560 dilutions (samples were diluted in 0.3% milkpowder). The test samples (in duplicate) were applied in the same dilutions. All samples were incubated for 2 h at 37°C. Bound vWF was detected with rabbit anti-human vWF antibodies labelled with horse radish peroxidase (anti-vWF-Ig-HRP, Dako) (1/3000 in 0.3% milkpowder) after 1 h incubation at RT. Visualisation was obtained with ortho-phenylenediamine (OPD, Sigma) and the colouring was stopped with 4 M H 2 SO 4 . The absorbance was determined at 490 nm. After each incubation step the plates were washed with TBS, 0.1% Tween-20, 3 times after coating and blocking and 12 times elsewhere.
vWF-collagen Binding (vWF:CBA ELISA)
Microtiter plates (96-well) were coated overnight at 4°C with different kinds of collagen (100 l/well). Rat tail collagen type I (Collaborative Biomedical Products, Bedford, MA, USA) was coated at a concentration of 50 g/ml. Human collagen types I, III (Sigma), VI and calf skin collagen type I (Sigma) were coated at 25 g/ml. The human types I, III and calf skin collagen type I used, were previously dialysed for 48 h against PBS. Rat tail collagen type I and human collagen type VI were diluted in PBS before coating. Plates were blocked with 3% milkpowder for 2 h at RT (250 l/well). Next, dilution series (1/2 in 0.3% milkpowder) of rvWF (all molecular weight multimers) were added and incubated for 1.5 h at RT or for 2 h at 37°C for rat tail collagen type I and human collagen type VI. Bound vWF was detected with anti-vWFIg-HRP (1/3000 in 0.3% milkpowder) after 1 h incubation at RT. Visualisation was performed as described above. After each incubation step the plates were washed with PBS, 0.002% Tween-80 or with PBS, 0.1% Tween-20 for rat tail collagen and human collagen type VI, as described above.
Competition ELISA
The ELISA was performed as described for vWF:CBA ELISA except that serial dilutions of mAb 82D6A3 were preincubated for 30 min at RT with constant amounts of rvWF in a preblocked plate. Samples were then added to each collagen containing well and were incubated for 2 h at 37°C before bound vWF was detected after incubation with anti-vWF-Ig-HRP.
SDS-PAGE and Western Blotting
Samples were run on a 7.5% running gel and a 4% stacking gel (15) and were transferred to a nitrocellulose membrane. The membrane was blocked with 3% milkpowder, washed three times with PBS 0.05% Tween-80 and incubated with anti-vWF-Ig-HRP (1/3000 in PBS, 0.3% milk powder) for 1 h at RT. After 10 washing steps the protein was detected with ECL reagent (Amersham, Pharmacia, Biotech).
Results
Construction of Mutant vWF
Alignment of the amino acid sequence VWTLPDQC (at position 1125-1136) in vWF with the sequence of the N-and Q-peptides is shown in Fig. 1 . Four conserved amino acids were mutated to alanine resulting in the following mutant vWF sequence: VATAPAAC (Fig. 1) . The mutations were introduced with the use of the QuickChange™Site-Directed Mutagenesis Kit as described in Materials and Methods. Part of the resulting pNUT-mutant-vWF-plasmids was sequenced to confirm the presence of the desired mutations. One of these plasmids (7.8-vWF) was selected to perform transfection of a fur-BHK cell line.
Expression, Purification and Characterization of Mutant vWF
The levels of expression of 7.8-vWF in the cell culture supernatant were measured in a vWF:Ag ELISA and were around 20 g/ml. These levels were in the range of those for WT-vWF (~10 g/ml) and ⌬A3-vWF (~20 g/ml) (7). Recombinant vWF was partially purified from cell culture supernatant by ion exchange chromatography and was assayed by SDS-PAGE under reducing conditions followed by Western blot to analyse subunit composition (Fig. 2) . No provWF was detected indicating that furin effectively removed the propeptide as described (7) .
Further purification of 7.8-vWF by heparin chromatography revealed the presence of vWF-fractions with low (33%), medium (21%) and high (46%) affinities for heparin. The same elution profile with similar relative levels: 36, 17, and 47% respectively for WT-and 38, 19 and 43% respectively for ⌬A3-vWF was found (not shown). The different affinities previously were found to correlate with the presence of LMW, MMW and HMW multimers respectively (14) .
Binding of 7.8-vWF to Rat Tail Collagen Type I
To study whether the region in vWF at position 1125-1136 contributes to collagen binding, 7.8-vWF-binding was first tested on rat tail collagen where the peptides selected by phage display had an optimal inhibiting effect (1). Fig. 3 shows that 7.8-vWF bound to rat tail collagen with the same affinity as ⌬A3-vWF. WT-vWF on the other hand consistently bound with a 2-fold lower affinity to rat tail collagen, as did vWF purified from plasma or another WT-vWF construct transiently expressed in COS cells (a gift from Dr. Ribba, Paris, INSERM U143).
Inhibition ELISA with mAb 82D6A3, a mAb that binds to the A3-domain of vWF and inhibits vWF-binding to human collagen types I and III (9) revealed that this mAb inhibits the 7.8-vWF-binding and WT-vWF-binding to rat tail collagen type I for 50%. No effect of the mAb was seen on the binding of ⌬A3-vWF (Fig. 4) . The sequence in vWF which could be aligned with the sequence of the peptides therefore is not the actual epitope of mAb 82D6A3 which was corroborated by the finding that 7.8-vWF was still recognized by mAb 82D6A3 whereas ⌬A3-vWF was not (Fig. 5) . Fig. 1 (A) Alignment of the sequence of N-and Qpeptides with the sequence of vWF and (B) sequence of primers used to introduce desired mutations. A) Amino acid sequence of the N-and Q-peptides, selected by phage display, that inhibit the vWF-binding to collagen aligned with the corresponding vWF peptide sequence (1). B) Part of the vWF DNA sequence and primers used to introduce the desired mutations. Nucleotides that were changed are in bold face, EagI restriction site is in italic. The corresponding amino acids of the original vWF sequence and of the mutated sequence are also given Fig. 2 Western blot analysis of recombinant vWF proteins after expression in a furine overexpressing BHK cell line. Recombinant vWF proteins were purified from the culture medium through ion exchange chromatography and were analysed under reducing conditions on a 7.5% SDS-polyacrylamide gel. Samples were transferred to a nitrocellulose membrane and were detected with anti-vWF-Ig-HRP. Lanes 1 and 2: WT-and 7.8-vWF respectively 
Binding to Different Types of Collagen
The peptides also inhibited vWF-binding to calf skin and to human collagen type I but with IC 50 values 5 to 10 times higher than for rat tail collagen (1) . Thus binding of 7.8-vWF was studied on those two types of collagen and in addition on human collagen types III and VI that are also abundant in the vessel wall and that show a detectable binding of vWF in a static binding assay.
No difference in binding characteristics of WT-vWF, 7.8-vWF and plasma vWF was observed on calf skin collagen (Fig. 6A) or on human collagen types I and III (not shown), whereas ⌬A3-vWF did not bind to these collagens. The lack of binding of ⌬A3-vWF is in agreement with previous results (7) .
On the other hand, binding to GuHCl-extracted human type VI collagen revealed that not only 7.8-vWF but also ⌬A3-vWF bound to this type of collagen (Fig. 6B) . The latter is in agreement with the findings of Hoylaerts et al. (9) where it was shown that the A1-domain and not the A3-domain was the main binding site for this type of collagen. Also here, WT-vWF or vWF purified from plasma bound with a lower affinity to collagen type VI than 7.8-and ⌬A3-vWF, that bound 3.6 times better.
Discussion
In a previous study (1), we selected two cyclic peptides (N-and Q-peptide) by phage display, that were able to inhibit vWF-binding to collagen. These peptides can be a starting point for the development of new antithrombotic agents.
In addition, the sequence of those peptides could be aligned with the sequence in vWF at position 1129-1136 just outside the A3-domain. However, the linear peptide corresponding to the vWF sequence itself was not able to inhibit vWF-binding to collagen, which could have been due to the peptide not having the correct conformation needed for binding (1) . To study whether or not amino acids 1129-1136 of vWF are involved in collagen binding, i.e. whether the alignment resulted in the identification of a new collagen binding site in vWF, we mutated the VWTLPDQC sequence in vWF to VATAPAAC.
Expression of this mutant vWF (7.8-vWF) in a fur-BHK-cell line resulted in well processed 7.8-vWF as no provWF was detected (Fig. 2) . The 7.8-vWF also had the HMW multimers as could be deduced from heparin chromatography. However, binding studies of this mutant vWF (Fig. 3, 6 ) to rat tail, human and calf skin collagens type I, to human collagen types III and VI, revealed no contribution of the vWF sequence at position 1129-1136 in binding to any of these collagens as no decrease in binding was observed with this mutant vWF. Thus, although the N-and Q-peptides did inhibit the vWF-collagen interaction, the resulting alignment with the vWF sequence did not identify a collagen binding site, pointing out that alignments (although with a high percentage of identity) do not always result in identification of binding epitopes.
It was previously shown that the phages bound to collagen and to mAb 82D6A3 but that the cyclic peptides and the linear vWF peptide did not prevent the interaction of vWF with 82D6A3, which may be either due to the fact that this sequence in vWF is not the actual epitope of mAb 82D6A3 or that the low affinity peptides were not able to compete with the high affinity interaction between the (1) . As 7.8-vWF is still recognised by mAb 82D6A3, whereas ⌬A3-vWF is not (Fig. 5) , it is now however clear that this sequence in vWF is not the actual epitope in vWF. Thus the N-and Q-peptides represent a mimotope of the vWF sequence and not the epitope.
However, the binding studies of 7.8-vWF and ⌬A3-vWF led to the following interesting observation. As is known, the main binding site of vWF to GuHCl-solubilized human collagen type VI is not the A3 but the A1-domain as was shown by the use of anti-A3 and -A1 inhibitory antibodies (9) . We here could fully proof this by showing that ⌬A3-vWF indeed binds to collagen type VI (Fig. 6B) . However, suprisingly, both ⌬A3-vWF as well as 7.8-vWF bind more avidly to collagen type VI than WT-or plasma vWF. In addition, similar findings were obtained with rat tail collagen type I: first of all, ⌬A3-vWF also binds to rat tail collagen and second both ⌬A3-and 7.8-vWF consistently bind stronger than WT-vWF or vWF purified from plasma. These observations are not due to the presence of higher molecular weight multimers in ⌬A3-and 7.8-vWF than in WT-vWF since (a) the heparin-column elution profiles of the three recombinant proteins was similar, (b) ⌬A3-vWF showed a normal distribution of the multimers (7) and (c) 7.8-vWF bound to human collagen types I and III with the same affinity as WT-vWF. Rat tail collagen type I thus in this respect seems to behave as human collagen type VI (Fig. 4) . However, experiments using mAb 82D6A3 indicated that binding of WT-vWF and 7.8-vWF to rat tail collagen was dependent on the A3-domain by up to 50% (Fig. 4) , which is in contrast with data obtained with human collagen type VI where mAb 82D6A3 had no effect on vWF-binding. In contrast antibody AJvW-2, against the A1-domain, caused a full inhibition of binding to human collagen type VI (9) . Interaction of vWF through its A1-domain (and A3-domain) with collagen type VI was also shown by Mazzucato et al. (10) . It is therefore very likely to hypothesize that vWF may also bind to rat tail collagen through its A1-domain. We however could not fully proove this as mAb AJvW-2 was not available and as other anti-A1-vWF mAbs 701 and 723 (a gift from Dr. Girma), which inhibit ristocetin and botrocetin induced platelet agglutination like AJvW-2, had no effect on vWF-binding to collagen type VI or to rat tail collagen. That both ⌬A3-and 7.8-vWF bind better to human collagen type VI and to rat tail collagen type I seems to imply that the presence of the A3-domain or the correct sequence 1129-1136 to some extent attenuates the collagen binding activity of the A1-domain. An effect of the A3-domain on the activity of the A1-domain recently has been described by Obert et al. (16) : the snake venom bitiscetin binds to the A3-domain and by this stimulates binding of vWF to GPIb via the A1-domain.
In conclusion, the vWF sequence VWTLPDQC, situated just outside the A3-domain, and aligning well with the sequence of the Nand Q-peptides, previously shown to inhibit vWF-binding to collagen (1), is not a new collagen binding site nor is the sequence the epitope of the mAb 82D6A3. The sequences identified through phage display therefore only mimic the relevant vWF sequence. It is clear from this study that, although we could successfully isolate inhibitory peptides with the use of phage display, the alignment of these peptides with the vWF sequence, although with a high percentage of sequence identity, did not result in the identification of a new binding site.
However, suprisingly removal of the A3-domain or changing the vWF sequence at positon 1129-1136 just outside the A3-domain resulted in an increase of vWF-binding to human collagen type VI and to rat tail collagen type I, implying that these changes result in a different conformation of probably the A1-domain with an increased binding to these collagens as a consequence.
